Full-Time

Medical Doctor

Montefiore Einstein

Montefiore Einstein

1,001-5,000 employees

Compensation Overview

$160k - $200k/yr

Bronx, NY, USA

In Person

Category
Medical, Clinical & Veterinary (1)
Requirements
  • Medical Doctor

Company Size

1,001-5,000

Company Stage

N/A

Total Funding

$4.9M

Headquarters

New York City, New York

Founded

N/A

Simplify Jobs

Simplify's Take

What believers are saying

  • New York awarded Montefiore $41.475M cybersecurity grant in 2026.
  • $4.5M Mother Cabrini grant boosts Moses Campus nursing on May 14, 2025.
  • Mass casualty exercise with Orange County OEM on June 10, 2025.

What critics are saying

  • Steidl's University of Utah adjunct role diverts expertise within 12-24 months.
  • Roshon Therapeutics advances Steidl's drugs independently in 12-18 months.
  • Mount Sinai's $11.8M funding erodes Bronx patient retention in 18-24 months.

What makes Montefiore Einstein unique

  • Ulrich Steidl named director of NCI-designated MECCC on April 7, 2026.
  • Steidl's pre-leukemic stem cell research advances precision cancer prevention.
  • Multidisciplinary committee reduces ICU deep sedation per Lancet study.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Montefiore Einstein who can refer or advise you

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Paid Vacation

Paid Holidays

Paid Sick Leave

Health Savings Account/Flexible Spending Account

Tuition Reimbursement

Gym Membership

Life Insurance

Training Programs

Conference Attendance Budget

Company News

PR Newswire
Apr 7th, 2026
Ulrich Steidl, M.D., Ph.D., named director of Montefiore Einstein Comprehensive Cancer Center.

Ulrich Steidl, M.D., Ph.D., named director of Montefiore Einstein Comprehensive Cancer Center. Apr 07, 2026, 14:43 ET Internationally Renowned Cancer and Stem Cell Researcher to Lead Bronx-Based NCI-Designated Center BRONX, N.Y., April 7, 2026 /PRNewswire/ - International leader in blood cancer and stem cell research, Ulrich Steidl, M.D., Ph.D., has been named director of the Montefiore Einstein Comprehensive Cancer Center (MECCC) and vice president of cancer medicine at Montefiore Einstein. He has acted as interim director of MECCC, which is a National Cancer Institute (NCI)-designated comprehensive cancer center, since late 2025. "I am deeply honored to accept the leadership of MECCC," said Dr. Steidl. "We have a tremendous team composed of exceptional clinicians, researchers, and administrators who are deeply dedicated to our patients, our community, and cutting-edge cancer care and innovative science. I look forward to working together as we advance our mission to reduce the burden of cancer in the Bronx and beyond, and drive innovation that improves the lives and well-being of people in our borough and around the world." Dr. Steidl has held a series of leadership positions within MECCC, having previously served as program leader, associate director for basic science, and deputy director. At Montefiore Einstein, he also held key roles as the associate chair for translational research in the department of oncology and interim director for the Ruth L. and David S. Gottesman Institute for Stem Cell Research and Regenerative Medicine. Dr. Steidl will continue to serve as chair of the department of cell biology at Albert Einstein College of Medicine. Since joining Montefiore Einstein in 2008, Dr. Steidl has established himself as an innovative and deeply committed scientist, collaborator, and mentor. His basic and translational research, funded by the National Institutes of Health, non-profit foundations, and philanthropy, focuses on defining the characteristics of pre-leukemic stem cells, their heterogeneity, and understanding their progression to leukemic stem cells, and developing drugs to interrupt this process. He has made seminal discoveries and contributions to the field. He was among the first researchers to demonstrate the existence of pre-cancerous stem cells, and how myelodysplastic syndrome, a common precursor of acute myeloid leukemia, arises and progresses from defective blood-forming stem cells. Lessons learned from Dr. Steidl's work in blood cancers have been adopted in many other tumor types and have jump-started the concept of 'precision prevention' of cancers and 'interception' of their progression and relapse. His work has directly contributed to the advancement of several experimental drugs now in clinical trials. In addition, he is an inventor on numerous patent filings and a co-founder of successful biotech startups. Widely recognized for contributions to research and mentorship, Dr. Steidl has earned numerous awards. At Einstein, he received the Saul R. Korey Award in Translational Science and Medicine in 2020 and the Marshall S. Horwitz Award for Research Excellence in 2025. He is a four-time recipient of Einstein's Julius Marmur Mentorship Award for Outstanding Mentoring in Graduate Research. Many of his graduate and postdoctoral trainees have gone on to hold faculty and leadership positions at prominent institutions worldwide. Dr. Steidl's additional honors include the Scholar Achievement Award from Blood Cancer United (formerly the Leukemia & Lymphoma Society) in 2019, the Outstanding Investigator Award from the NCI in 2021, and most recently, the 2025 McCulloch & Till Award from the International Society for Experimental Hematology (ISEH) and the 2025 All-Star Award from the V Foundation for Cancer Research. He is an elected member of the Association of American Physicians and the American Society for Clinical Investigation and has served as both vice president and president of the ISEH. About Montefiore Einstein Comprehensive Cancer Center Montefiore Einstein Comprehensive Cancer Center (MECCC) is a National Cancer Institute (NCI)-designated comprehensive cancer center and a national leader in cancer research and clinical care located in the racially and ethnically diverse borough of the Bronx, N.Y. MECCC combines the exceptional science of Albert Einstein College of Medicine with the multidisciplinary and team-based approach to cancer clinical care at Montefiore Health System. Founded in 1971 and an NCI-designated cancer center since 1972, MECCC is redefining excellence in cancer research, clinical care, education and training, and community outreach and engagement. Its mission is to reduce the burden of cancer for all, especially people from historically underrepresented groups. SOURCE Montefiore Einstein Comprehensive Cancer Center

Montefiore St. Luke's Cornwall Hospital
Feb 9th, 2026
Montefiore St. Luke's Cornwall Appoints Michelè (Michael) Salituro, CPA, as Senior Vice President and Chief Financial Officer

Montefiore St. Luke's Cornwall appoints Michelè (Michael) Salituro, CPA, as Senior Vice President and Chief Financial Officer. Feb 9, 2026 Hospital Newburgh, NY - Montefiore St. Luke's Cornwall (MSLC) is pleased to announce the appointment of Michelè (Michael) Salituro, CPA, as Senior Vice President and Chief Financial Officer, effective February 2, 2026. Mr. Salituro brings nearly 30 years of experience in financial leadership, Michael has a formidable background in healthcare finance, financial reporting, auditing, and revenue cycle. Prior to joining Montefiore St. Luke's Cornwall, he served as Partner at BDO USA, P.C... His Partner role included overseeing multi-entity and multi-location concurrent audit engagements from planning to completion. Prior to his tenure at BDO, Mr. Salituro held various positions in the healthcare field including Vice President of Finance in a not-for-profit healthcare system and Senior Vice President and Chief Financial Officer in a for-profit hospital. Mr. Salituro holds a Bachelor of Business Administration from Iona University and a Master of Business Administration from the University of Phoenix. In his role as CFO, Mr. Salituro will be administratively responsible for all services of the Finance Division and for the management and operations of all financial services in the hospital. In addition, he will collaborate closely with all leaders to ensure the financial stability and growth of MSLC's services. "We are excited to welcome Michael to Montefiore St. Luke's Cornwall," said Daniel Maughan, MSLC President and CEO. "His extensive experience, and strong healthcare background will be instrumental as we continue to advance our mission and strengthen our organization for the future." Montefiore St. Luke's Cornwall proudly welcomes Mr. Salituro to the organization.

Healthcare IT News
Dec 16th, 2025
New York awards hospitals more than $300M for IT and cyber investments

New York awards hospitals more than $300M for IT and cyber investments. The state announces new funding aimed at expanding electronic health records, strengthening cybersecurity, and increasing telehealth and post-acute care services. New York has announced new technology funding for hospitals, disbursed under its Statewide Health Care Facility Transformation Program. This year's money - more than $300 million - is earmarked for IT, cybersecurity, telehealth and other digital transformation efforts, and is to be divided among 22 hospitals that span every region of the Empire State. The state has already awarded more than $1.75 billion in previous rounds to providers working to improve access, equity and quality of care, N.Y. Gov. Kathy Hochul noted this past Friday. "By modernizing our hospitals' IT infrastructure and protecting patients' information, we're strengthening the foundation of health care in New York State," she said in a statement. "These investments will help ensure that hospitals have the tools they need to safeguard patient data, expand telehealth services and deliver a healthier future for all New Yorkers." This year's funding for critical health information technology infrastructure modernization, cybersecurity and patient information security, and telehealth expansion - $309,047,122 - is largely aimed at supporting financially distressed providers, according to Hochul's statement. Ten hospitals received the most funding ($195,127,664) for electronic health record projects. Those are Blythedale Children's Hospital, Calvary Hospital, Richmond Medical Center, Rome Memorial Hospital, Samaritan Medical Center, St. Joseph's Hospital, Yonkers Stony Brook University Hospital, The Brooklyn Hospital Center, Westchester Ellenville Hospital and Wyckoff Heights Medical Center. Individual awards ranged from $54,098,779 for Richmond's EHR needs to $1.2 million for those at Blythedale Children's. Eight hospitals - Adirondack Medical Center, Claxton-Hepburn Medical Center, Ellis Hospital, Montefiore Health System, Niagara Falls Memorial Medical Center, One Brooklyn Health System, The Rochester General Hospital and Calvary Hospital - all received funding for cybersecurity projects. The total allocation for healthcare information security represents the next largest pool of funding at $101.7 million under the program. Montefiore, a Bronx-based health system, received the highest award for security upgrades at $41.475 million, while the medical center in Niagara Falls received the smallest award at $530,000. Four projects received funding for telehealth with a total allocation of nearly $5.28 million. Those are Champlain Valley Physicians Hospital Medical Center ($1.015 million), Columbia Memorial Hospital ($290,000), SUNY Health Science Center at Syracuse ($2.43 million) and United Health Services Hospitals ($1.542 million). Rounding out the total pool of this year's healthcare sector transformation funding program round, Mount Sinai Hospital will receive $11,768,743 for population health management technologies that accelerate the transition from hospital to home. Of note, when New York State Medicaid expanded its patient coverage to include remote patient monitoring services provided by clinical staff on Jan. 1 this year, the new reimbursement was also viewed as an opportunity to help providers and payers reduce hospital stays. "Providers can extend their care into patients' homes without increasing clinician workloads," noted Alexandria Foley, vice president of nursing and care delivery at Brook Health, an RPM services vendor. "And payers can help members improve long-term health, slow disease progression and reduce costly admissions," she explained to Healthcare IT News in April. The larger goals of the New York Statewide Health Care Facility Transformation Program are to preserve and expand essential healthcare services as part of a broader commitment that has directed more than $4.7 billion in healthcare capital funding statewide since 2016, Hochul noted. But, in addition to the health IT, cybersecurity and telehealth (IV and V of the funding program), the state also announced plans earlier this year to invest $188 million for hospital modernization through the Healthcare Safety Net Transformation Program. That program included awards for EHR integrations, tech upgrades for emergency departments and neonatal intensive care units and other digital health efforts. "Every person should have access to affordable, reliable healthcare regardless of the ZIP code they live in, and these investments will bring vital resources to underserved New Yorkers," said Hochul in a statement at the time. "With these investments, we are focused on developing safe, reliable and connected patient-centered care," said Dr. James McDonald, commissioner of the New York Department of Health, in a statement Friday. "By expanding data capabilities and improving cybersecurity defenses, we're enhancing clinical decision making across the state's healthcare network."

Sleep Review
Oct 16th, 2025
People Who Receive Less Sedation When Ventilator-Dependent More Likely to Return to Independent Living After Hospitalization

People who receive less sedation when ventilator-dependent more likely to return to independent living after hospitalization. A Montefiore Einstein study finds that heavy use of deep sedation during mechanical ventilation increases the risk of long-term disability, prompting a shift toward early mobilization and non-opioid, symptom-focused care. * Deep sedation was associated with greater risk of adverse discharge outcomes, including loss of independence. * Patients receiving symptom-targeted, non-opioid treatments fared better in regaining functional ability after hospitalization. * Sedation aimed at promoting rest may instead disrupt restorative sleep, contributing to delirium and muscle loss. * Montefiore Einstein has launched a multidisciplinary mobilization committee to reduce deep sedation and encourage early movement in ICUs. Deep sedation - when medications keep patients from being fully conscious and not easily aroused - is commonly used in intensive care units (ICUs) across the country with the aim of preventing ventilated patients from experiencing emotional distress and/or pain during their critical recovery. The problem is that when a patient is deeply sedated, it inhibits them from being able to move their bodies. New research published in The Lancet Respiratory Medicine shows that in a cohort of more than 10,000 people, patients who received a high proportion of deep sedation while mechanically ventilated had a greater risk of adverse discharge - losing their ability to live independently - compared to patients who did not receive deep sedation. The findings, from investigators in the department of anesthesiology at Montefiore Einstein, suggest that patients who received targeted, symptom-focused treatments with non-opioid medications, instead of deep sedation, had higher rates of independent living after being discharged from the hospital. "In this study, we found sedative medications were more likely to be delivered to patients to aid with sleep and rest; however, use of sedative medications can actually strip the exhausted patient of the healthy restorative sleep they need most during illness," says author Matthias Eikermann, MD, PhD, Francis F. Foldes Professor and chair, department of anesthesiology at Montefiore Einstein, in a release. "Our data shows this lack of quality sleep leads to greater rates of immobility in the ICU, which compounds into even more delirium and greater loss of the muscles and nerves needed during recovery." With evidence from this study, the department of anesthesiology spearheaded the creation of a system-wide mobilization committee, including the departments of anesthesiology, medicine, and rehabilitation medicine (including physical therapy and respiratory therapy teams) and nursing, with the goal of reducing the use of deep sedation and increasing early mobilization in the ICUs. This multidisciplinary group will conduct targeted rounds in the ICUs to identify barriers to early mobilization and develop strategies to implement patient-centered interventions. Efforts are supported by a digital patient board in Montefiore Einstein's electronic record system to track these newly developed protocols and a new surgical ICU order set to ensure clinicians have the tools needed to identify alternative pain treatments. By deploying a new symptom-focused treatment strategy, Montefiore Einstein investigators believe that providers will be able to more comprehensively evaluate patients and recognize symptoms of emotional distress, treating them accordingly with antipsychotics or non-opioid analgesics. "Our hope is that the data published in this investigation will fuel national efforts to improve education about deep sedation and adherence to evidence-based guidelines," Eikermann says. "The ultimate goal is to enhance overall patient care and help people return to the lives they want to live with their loved ones."

Montefiore St. Luke's Cornwall Hospital
Jul 16th, 2025
Montefiore St. Luke's Cornwall Participates in Countywide Emergency Response Exercise

Orange County, New York [June 10, 2025] - Montefiore St. Luke's Cornwall (MSLC) Emergency Management team partnered with the Orange County OEM to conduct a large-scale mass casualty exercise simulating an international plane crash into the Hudson River.